Article citationsMore>>
Katsumata, N., Yasuda, M., Isonishi, S., Takahashi, F., Michimae, H., Kimura, E., Aoki, D., Jobo, T., Kodama, S., Terauchi, F., Sugiyama, T., Ochiai, K., Japanese Gynecologic Oncology Group. (2013) Long-Term Results of Dose-Dense Paclitaxel and Carboplatin Versus Conventional Paclitaxel and Carboplatin for Treatment of Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (JGOG 3016): A Randomised, Controlled, Open-Label Trial. The Lancet Oncology, 14, 1020-1026.
https://doi.org/10.1016/S1470-2045(13)70363-2
has been cited by the following article:
-
TITLE:
Three Weeks Carboplatin/Paclitaxel versus Weekly Regimen in Egyptian Women Cohort Treated for Ovarian Carcinoma
AUTHORS:
A. Mounir, E. E. Ibrahim
KEYWORDS:
Epithelial Ovarian Carcinoma, Carboplatin/Paclitaxel, Weekly versus Every Three Weeks
JOURNAL NAME:
Journal of Cancer Therapy,
Vol.12 No.2,
February
19,
2021
ABSTRACT: Introduction: Epithelial Ovarian Carcinoma (EOC) comprises the vast
majority (almost 90%) of ovarian carcinomas. Chemotherapy is the main treatment
in ovarian cancers. The standard of care in the chemotherapeutic is the combination
of a platinum (carboplatin or cisplatin) and a taxane (paclitaxel or docetaxel).
Studies were done to determine whether this combination to be given weekly or every
3 weeks. Patient and Method: Inclusion criteria: 1) Female patients between
the ages of 17 - 78 years. 2) Baseline hematological, renal and liver laboratory
profiles were within accepted ranges. 3) Performance status of the patients was
0-II. 4) Patients were pathologically proven ovarian cancer. 5) A follow-up period
for at least 6 months was required. Exclusion criteria: 1) Patients who had double
malignancy were excluded. 2) Performance status more than II. 3) Other comorbidity. Results: We reviewed 69 female patients with EOC, with 60% received every
three weeks regimen. Mean age was 53.22 years. At a median follow up of 45.9 months,
there was no significant different between the two protocols in terms of mean PFS,
62.35 months (95% CI: 50.08 - 74.63 months) for the three-weekly cohort, and 69.25
months (95% CI: 55.24 - 83.26 months) for weekly protocol (p = 0.613). The three
weekly regimen patients had a higher incidence of hospital admission (40% vs 18.5%
for the weekly protocol patients), but it didn’t reach a statistical significance
(p = 0.063). The three weekly protocol had a significantly higher incidence of causing
a neutropenic fever (p = 0.003). Conclusion: In our cohort of Egyptian women
with EOC, no significant difference in PFS was found when compared the weekly Carboplatin/paclitaxel
when compared to the classic three weeks, although the weekly protocol may be causing
less febrile neutropenia and fewer hospital admissions.
Related Articles:
-
Takanori Ayabe, Masaki Tomita, Eiichi Chosa, Makoto Ikenoue, Yukie Shirasaki, Kunihide Nakamura
-
A. Mounir, E. E. Ibrahim
-
Shimaa Ahmed, Mayada Fawzy, Khalid Rezk, Wessam Elshrif, Mohamed Alaa, Mohamed M. H. Abd Ellah
-
Hiroshi Takagi, Satoshi Ichigo, Kazutoshi Matsunami, Haruna Takagi, Tsuneko Ikeda, Takayuki Murase, Atsushi Imai
-
Hale Aslan, Sedat Öztürkcan, Erdem Eren, Mehmet Sinan Başoğlu, Murat Songu, Erkan Kulduk, Ahmet Erdem Kılavuz, Hüseyin Katılmış